AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02731287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
Study NCT02546882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction
Description: 1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
Study NCT02546882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 1 ml saline was injected for 1 cm2 area.
Study NCT05592821 — intervention group
Intervention type: PROCEDURE
Intervention: dental implant placement
Description: In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
Study NCT00414570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18]F-FLT PET scan
Description: Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
Study NCT03824951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 iCAR NK Cells
Description: Anti-CD19 iCAR NK Cells injection
Study NCT01977365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth promotion based on child centered approach
Description: - Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers.
Study NCT00383071 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 vaccine
Description: Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
Study NCT00383071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Once subjects achieved a high antibody titer (>1:160), they could begin apheresis to collect plasma.
Study NCT01707329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Study NCT01707329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib+chemotherapy
Description: Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Study NCT02983240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Uterine Pacemaker
Description: The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
Study NCT02070406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02070406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT02070406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Description: Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
Study NCT02070406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: NY-ESO-1157-165 peptide pulsed DC vaccine given ID
Study NCT02070406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT02070406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study NCT02070406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT02070406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00965406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK and intensive insulin therapy
Description: GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
Study NCT00965406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIK and intensive insulin therapy
Description: GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
Study NCT00664755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study.
Study NCT00664755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study.
Study NCT03017365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable Resistance Training
Description: traditional machine-based resistance training
Study NCT03017365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable Resistance Training
Description: free weight resistance training using unstable devices
Study NCT03017365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor/Abductor Resistance Training
Description: machine-based adductor/abductor resistance training
Study NCT03591094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active
Study NCT03591094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04497298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
Study NCT04497298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
Study NCT04497298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
Study NCT04497298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline solution (0.9% NaCl)
Study NCT04497298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline solution (0.9% NaCl)
Study NCT02527655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-Based Physical Activity and Active Transportation
Study NCT03591055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA, medication review, exercise and cognitive stimulation
Description: Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
Study NCT00740922 — intervention group
Intervention type: DRUG
Intervention: Sterile becaplermin gel vs. sterile placebo gel treatment 1
Description: Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
Study NCT02816125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acid
Description: SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
Study NCT02816125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
Study NCT02624011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 days of habitual physical activity followed by 7 days of reduced physical activity
Description: Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
Study NCT03111264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP
Description: The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills.
Study NCT03461471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise intervention
Study NCT01531998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
Study NCT01531998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8.
Study NCT03111264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP+
Description: The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
Study NCT01555905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold PEP or IMT device Phillips-Respironics
Description: The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
Study NCT03695393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Therapy
Description: The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
Study NCT04280887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPad
Description: Ultrasound bed wetting alarm
Study NCT02961517 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
Study NCT00326417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
Study NCT00326417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 150mg
Description: A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
Study NCT00326417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100mg
Description: A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
Study NCT00326417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
Study NCT01898364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
Study NCT04699214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar (recombinant human endostatin injection)
Description: The experimental group is Endostar combined with AI
Study NCT04699214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endostar (recombinant human endostatin injection)
Description: The experimental group is Endostar combined with AI
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (FU)
Description: 400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (FU)
Description: 400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
Study NCT01531998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy.
Study NCT01531998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week.
Study NCT01531998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
Study NCT03999580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance
Study NCT03999580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance
Study NCT04699214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy AI
Description: AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (FU)
Description: 2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT03050814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (FU)
Description: 2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
Study NCT04421924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thrombelastogram
Description: Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
Study NCT04421924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care
Description: 2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
Study NCT02438904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Positive Stem Cell Infusion
Description: Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
Study NCT02438904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi device
Description: Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
Study NCT02808741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 SDD
Description: Pharmacokinetics area under curve
Study NCT02808741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR
Description: Pharmacokinetics area under curve
Study NCT02808741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR Fasting
Description: Pharmacokinetics area under curve
Study NCT02808741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR Fed
Description: Pharmacokinetics area under curve
Study NCT04111107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Agent
Description: Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
Study NCT04111107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care Regimens
Description: Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
Study NCT03586518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping.
Study NCT03586518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.